BirchBioMed reports positive results for keloid scars candidate FS2 in phase 2 trial
BirchBioMed has reported positive results from a phase 2 trial evaluating the use of topical FS2, the company’s antifibrotic platform therapy, in the treatment of keloid scars. The Canadian clinical-stage immunology company said that the double-blind study delivered statistically significant results compared to Mederma, a market leading scar cream and a vehicle (placebo cream) in […]